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Abstract
Background: Intercellular adhesion and biofilm production by Staphylococcus aureus makes these bacteria resistant
to antimicrobial therapy. Here, Methicillin-resistant Staphylococcus aureus (MRSA) strains were characterized and the
prevalence of genes encoding adhesion factors and biofilm formation was determined.
Results: All 248 MRSA isolates identified by cefoxitin disc diffusion were positive for the mecA gene. SCCmec-IV was
the most frequently detected genotype (92.7%) and SCCmec-IVa was also very prevalent (84.3%). The quantitative
microtiter plate assay showed that all the isolates were able to produce biofilm with levels ranging from high (21%)
to moderate (46.4%) to low (32.7%).
All the strains possessed the icaD/icaA genes and produced biofilm (P < 0.05). None of the isolates possessed the
bap gene. Furthermore, 94.8% of the isolates were positive for eno, 80.2% for clfA and for clfB, 78.2% for fnbA, 76.2%
for ebps, 62.2% for fib, 39.9% for cna and 29.0% for fnbB. Also, nearly 69.8% of the isolates were positive for the
gene sarA. All four agr groups were present: agr group 1 was predominant with 39.5%; agr group 3. agr group 2
and 3 strains carried more toxin-producing genes, and frequently produced more toxin. Sixty-six (26.6%) of the
strains were multidrug resistant. All were vancomycin sensitive. Agr group I is more resistant to ciprofloxacin and
gentamicin while agr group III is more resistant to erythromycin. Maximum sensitivity was to gentamicin and SXT,
and they could be considered drugs of choice for controlling MRSA mediated infections in this region.
Conclusions: Biofilm development in MRSA might be an ica dependent and one needs to investigate the
involvement of other global regulators, agr and sarA, and their contribution to the biofilm phenotype, as the high
rate of biofilm production among the studied strains of S. aureus.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA) is a
serious risk to hospitalized patients worldwide and charac-
terized by its resistance to antimicrobial treatment, and
more recently to vancomycin, the drug of last resort for
many strains of MRSA. In addition to its bacterial antibiotic
resistance, its ability to produce biofilm, a dynamic struc-
turally complex multilayered cellular matrix is another im-
portant complicating factor. Understanding the molecular
pathogenesis of S. aureus could assist in developing novel
prevention and treatment strategies. Biofilm synthesis is ne-
cessary for the survival and persistence of MRSA in its
hosts and is considered to be a major virulence factor [1]
and one of many, including extracellular toxins and surface
structures that are effective in the induction and continu-
ance of infection in the host [2]. Biofilm production is im-
portant during infection, providing defense against several
opposing mechanisms of host and protects the microor-
ganisms from antimicrobial agents [3]. The ability to form
biofilm is a trait associated with bacterial virulence and
many chronic bacterial infections [4]. Several genes are
involved in the manufacture and maintenance of biofilms
by staphylococci, of which the most extensively studied are
the icaA and icaD (intercellular adhesion A and B) genes
responsible for the synthesis of polysaccharide intercellular
adhesion (PIA) that includes N-acetylglucosamine as a
main component of the exopolysaccharide matrix sur-
rounding the bacterial cells within the biofilm [5–7]. The
protein components of the microbial surface recogniz-
ing adhesive matrix molecules have a high ability to
interact with the host extracellular matrix proteins like
collagen-binding protein (cna), fibrinogen binding pro-
tein (fib), elastin binding protein (ebpS), laminin bind-
ing protein (eno), fibronectin binding proteins A and B
(fnbA and fnbB) and clumping factors A and B (clfA
and clfB) [8].
Several virulence determinants of S. aureus are under the
control of two genetic loci namely sarA (staphylococcal
accessory regulator) and the agr quorum-sensing system.
SarA might impact methicillin-resistant Staphylococcus
aureus (MRSA) persistence in such infections by up regu-
lating the expression of many virulence factors including
biofilm formation to facilitate evasion of the host immune
system in late phases of growth. Inhibiting the production
of sarA protein might influence the down regulation of bio-
film and virulence factors [9].
Suppression of the agr quorum-sensing system is re-
quired for biofilm formation. Its recurrence in estab-
lished biofilms either through addition of auto-inducing
peptides (AIPs) or glucose depletion triggers biofilm
detachment [10–12]. Bacteria of S. aureus fall into four
polymorphic agr types (agr I, agr II, agr III, and agr IV)
based on the specificity of the auto- inducing peptides
(AIPs) with regard to the signal receptor agr C.
There are no data on either the virulence factors of the
microbial surface components recognizing adhesive matrix
molecules (MSCRAMM) family or factors responsible for
biofilm formation in methicillin resistance S. aureus in
Palestine. This study focused on exposing the genes encod-
ing adhesion factors and biofilm-forming capacity, and
those governing antibiotic resistances in strains of MRSA
isolated from Palestinian patients. It also evaluated the
correlation between biofilm production and the presence
of icaD, SarA and agr genes in the clinical isolates.
Results
Characterization of MRSA strains and antibiotic
susceptibility
From 2015 to 2018, 248 strains of MRSA: 78 (31.5%)
from infected wounds; 34 (13.7%) from blood culture; 25
(10.1%) from nasal secretions; 23 (9.3%) from urine; 88
of various other origins were collected from major hos-
pitals in the West Bank-Palestine.
By the cefoxitin disc-diffusion Resistance test (≤22mm),
the 248 bacterial isolates were identified as being pheno-
typically MRSA and confirmed them as such by targeting
the femA and mecA genes, which, respectively, separate
susceptible S. aureus from MRSA. All of the isolates tested
positive for the mecA gene by a PCR assay.
The susceptibility patterns of methicillin resistant iso-
lates to the other antimicrobials are presented in Table 1.
The cefoxitin disc-diffusion test showed that all 248 iso-
lates were resistant to methicillin and none were resistant
to vancomycin. However, sensitivity was high to varying
degrees to SXT, gentamicin, clindamycin, ciprofloxacin,
and erythromycin that were, respectively, 77.8, 76.6, 61.7,
55.6 and 34.3% (Table 1).
Aside from cefoxitin and B-lactams antibiotics (penicillin
G, amoxicillin/clavulanic acid, ceftriaxone and merope-
nem), the highest antibiotic resistance rates among the iso-
lates of MRSA were for erythromycin (65.7%), ciprofloxacin
(44.4%) and clindamycin (38.3%), followed by gentamycin
(23.4%) and SXT (22.2%). All the isolates were susceptible
to vancomycin (100%). Only, 66 (26.6%) isolates were MDR
and, of 52 strongly positive biofilm-producing isolates, 20
(38.5%) were MDR and 32 (61.5%) were non-MDR.
Three different SCCmec types were detected among the
isolates of MRSA that could be typed. Most of them
carried SCCmec type IV (230/248, 92.7%), followed by
SCCmec type I (11/248, 4.4%) and SCCmec type V (1/248,
0.4%). Also, 2.4% of the isolates could not be typed by
multiplex PCR. None of the isolates carried SCCmec type
II or III. The majority of the strains carrying SCCmec type
IV carried SCCmec-type IVa (84.3%), followed by type IVc
(4.8%), type IVd (1.2%) and type IVb (0.4%), and three pa-
tients provided two strains of type IVa/IVc (1.2%). Isolates
were classified as CA-MRSA when they possessed SCCmec
IV, as one of the subtypes IVa, IVb, IVc, IVd, or SCCmec
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type V and 231 CA-MRSA strains were found among all
the isolates. Out of 12 MRSA strains with SCCmec IVc, 9
and 7 isolates were resistant to erythromycin and clinda-
mycin with weak biofilm producers. All but one of the
SCCmec IVc were sensitive to gentamycin, ciprofloxacin
and SXT.
PCR screening of biofilm associated genes
Of the 248 strains of MRSA studied, 207 (83.5%) pos-
sessed the icaD gene and in 41 (16.5%) it was undetected.
This percentage of icaD-negative strains was surprisingly
high so detection of the icaA gene was undertaken which
showed that all 41 icaD-negative strains were icaA-posi-
tive. High prevalence of icaA and icaD genes has shown a
relationship to phenotypic biofilm formation.
None of the strains possessed the bap gene. The preva-
lence of sarA, eno, clfA, clfB, fnbA, ebps, fib, cna, and fnbB
genes were 69.8, 94.8, 80.2, 80.2, 78.2, 76.2 62.2, 39.9 and
29.0%, respectively (Table 2). The frequency of clfA/B and
fnbB genes of the agr group I were high at 92.9 and 52.0%,
respectively. The frequency of eno, fnbA, epbS, fib and cna
genes of the agr group III were also high at 97.6, 91.5,
84.1, 80.5 and 53.7%, respectively (Table 2).
The coexistence of the studied virulence genes was in-
vestigated in the 248 clinical isolates of MRSA, only nine
of which had all the genes investigated. Five had only the
eno gene. Despite these low prevalence rates, the other
234 strains possessed at least one other virulence gene.
Of the clinical isolates in which most virulence genes
were investigated for coexistence, 56 were positive for all
the genes but one, either eno (n = 29) or fnbB (n = 27)
gene. Of 42 clinical isolates, 18 strains were negative for
two genes, fnbB and fib genes and 24 were negative for
finbB and cna genes.
Determination of biofilm production by the microtiter
plate method
All the strains of MRSA produced biofilm. In the micro-
titer plate method for determining this and using the
mean OD570 of the negative control (0.07), values between
0.07 and 0.140 (2 × the negative control value of 0.07), were
considered to be strains that were weak producers, which
accounted for 81 (32.7%) strains, values between 0.140 and
here 0.280 (4 × the negative control value of 0.07) to be
moderate producers, which accounted for 115 (46.4%)
strains and values higher than 0.280 were strong producers,
which accounted for 52 (21.0%) strains (Table 3).
Among the 65.7 and 43.9% of high resistance of the
strains of MRSA to erythromycin and ciprofloxacin, 31.8
and 18.1% were moderate biofilm producers., respectively.
Among the 78 clinical isolates of S. aureus from
wounds, 37 (47.4%) were weak producers of biofilm, 34
(43.6%) were moderate producers and 7 (9%) were strong
producers. Of the 34 isolates from blood, 9 (26.5%) were
weak producers, 12 (35.3%) were moderate producers and
13 (38.2%) were strong producers. Of the 23 isolates from
urine, 6 (26.1%) were weak producers, eleven (5.5%) were
moderate producers, and 6 (26.1%) were strong producers.
Of the 25 nasal isolates, 6 (24%) were weak producers, 14
(56%) were moderate producers and 5 (20%) were strong
producers. Among the 88 isolates obtained from other dif-
ferent clinical samples, 23 (26.1%) were weak producers,
44 (50%) were moderate producers and 21 (23.9%) were
strong producers, of which half of the sputum samples
were strong producers (Fig. 1).
All the virulence genes were found in weak, moderate
and strong producers of biofilm. The least frequent
genes were the cna (39.9%) and fnbB (29%) genes, the
percentages of which were, respectively, 39.5 and 29.6%
for weak biofilm producers, 40.8 and 20.1% for moderate
biofilm producers, and 38.4 and 34.6% for strong biofilm
producers (Table 3).
The agr groups
Table 2 gives the agr groups of the strains of MRSA. The
248 strains separated into four agr groups with 98 (39.5%)
belonging to agr-I, making it the predominant type, 23
(9.3%) belonging to agr-II, 82 (33.1%) belonging to agr-II,
Table 1 Frequency of antibiotic resistance of MRSA strains and biofilm
Antibiotics Weak biofilm producer
(0.07 < ODs≤ 0.14)
Moderate biofilm producer





S n. (%) R n. (%) S n. (%) R n. (%) S n. (%) R n. (%) S n. (%) R n. (%)
Cefoxitin 0 (0%) 81 (32.7) 0 (0) 115 (46.3) 0 (0) 52 (20.9) 0 (0) 248 (100)
Penicillin 0 (0%) 81 (32.6) 0 (0) 115 (46.3) 0 (0) 52 (20.9) 0 (0) 248 (100)
Ciprofloxacin 49 (19.8%) 32 (12.9) 69 (27.8) 45 (18.1) 19 (7.6) 32 (12.9) 137 (55.2) 109 (43.9)
Clindamycin 50 (20.2%) 31 (12.5) 75 (30.2) 40 (16.1) 28 (11.2) 24 (9.7) 153 (61.6) 95 (38.3)
Erythromycin 29 (11.7%) 52 (20.9) 36 (14.5) 79 (31.8) 20 (8.0) 32 (12.9) 85 (34.2) 163 (65.7)
Gentamycin 69 (27.8%) 12 (4.8) 93 (37.5) 22 (8.8) 28 (11.2) 24 (9.6) 190 (76.6) 58 (23.3)
SXT 65 (26.2%) 16 (6.4) 92 (37.1) 23 (9.2) 36 (14.5) 16 (6.4) 193 (77.8) 55 (22.1)
Vancomycin 81 (32.7%) 0 (0) 115 (46.3) 0 (0) 52 (20.9) 0 (0) 248 (100) 0 (0)
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9 (3.6%) belonging to agr-IV and 36 (14.5%) were negative
regarding the agr PCR. There was no relationship
between agr specific groups and the genes encoding
MSCRAMM. Strains that belonged to the agr-I group
showed higher antibiotic resistance to ciprofloxacin and
gentamycin, compared to the other three agr groups.
Strains that belonged to agr-III group had higher
erythromycin (69.5%) and clindamycin (48.8%) resist-
ance compared to the other agr groups. Of the 66 MDR
strains, 20 belonged to the agr-I group and only 10, 11
and one belonged to the agr-II, agr-III and agr-IV
groups, respectively (Table 2).
Detection of the SarA gene
The sarA gene was found in 173 (69.8%) strains of MRSA.
Regarding phenotypic biofilm formation, 63 of 81 (77.7%)
were weak producers of biofilm, 85 of 115 (73.9%) strains
were moderate producers and 25 of 52 (48.1%) were
strong producers with a significant difference (P < 0.05).
There was a high prevalence of fib (83.4%), clfB and clfB
(80.4% each) and fnbB (81.9%) and fnbA (81.4%). Of the
strains of MRSA carrying the sarA gene, 46.9% were
MDR, and 63.2, 63.3 and 65.3%, 55.2 and 41.8% were re-
sistant to erythromycin, ciprofloxacin, clindamycin, genta-
mycin and SXT., respectively (Tables 2, 3).
Table 2 The presence of biofilm-related genes for each agr group
Agr group (%)
Biofilm Plate Titer (N = 248) AgrI AgrII AgrIII AgrIV NT SarA gene
Weak biofilm producer (n = 81, 32.7%) 30.6 17.4 43.9 66.7 13.9 77.7
Modertae biofilm producer (n = 115, 46.3%) 42.9 56.5 50.0 22.2 47.2 73.9
Strong biofilm producer (n = 52, 20.9%) 26.5 26.1 6.1 11.1 38.9 48.1
Total (n, %) (98, 39.5%) (23, 9.3%) (82, 33.1%) (9, 3.6%) (36, 14.5%) 173
SarA gene (173, 69.7%) 80.6 65.2 80.5 77.7 16.6
Adhesion Genes
icaD/ icaA(n = 248) 87.7 87.0 78.0 88.9 80.6 58.5
Eno (n = 235, 94.8%) 92.9 91.3 97.6 100.0 94.4 71.5
ClfA (n = 199, 80.2%) 92.9 87.0 89.0 55.6 27.8 80.4
ClfB (n = 199, 80.2%) 92.9 87.0 89.0 55.6 27.8 80.4
FnbA (n = 194, 78.2%) 87.8 78.3 91.5 66.7 25.0 81.4
EbpS (n = 191, 76.2%) 82.7 60.9 84.1 55.6 55.6 76.4
Fib (n = 154, 62.2%) 60.2 73.9 80.5 66.7 16.7 83.1
Cna (n = 99, 39.9%) 46.9 21.7 53.7 0.0 11.1 78.8
FnbB (n = 72, 29.0%) 52.0 21.7 13.4 11.1 11.1 81.9
Antibiotic Resistance
Cefoxitin/Penicillin (n = 248) 100.0 100.0 100.0 100.0 100.0 100
Erythromycin (n = 163) 59.2 60.9 69.5 33.3 86.1 63.2
Ciprofloxacin (n = 109) 58.2 56.5 20.7 33.3 52.8 63.3
Clindamycin (n = 95) 28.6 43.5 48.8 11.1 44.4 65.3
Gentamycin (n = 58) 27.6 21.7 11.0 22.2 41.7 55.2
SXT (n = 55) 19.4 21.7 11.0 11.1 58.3 41.8
MDR (n = 66) 22.4 43.5 13.4 11.1 61.1 46.9
Source of isolate
Wound (n = 78) 36.7 34.8 35.4 22.2 8.3 80.7
Blood (n = 34) 11.2 17.4 11.0 11.1 25.0 52.9
Nasal (n = 25) 11.2 13.0 8.5 0.0 11.1 64
Pus (n = 23) 8.2 8.7 13.4 22.2 0.0 95.6
Urine (n = 23) 1.0 0.0 11.0 22.2 30.6 43.5
Tissue (n = 13) 9.2 8.7 2.4 0.0 0.0 61.5
Sputum (n = 12) 3.1 8.7 6.1 0.0 5.6 58.3
Other sites (n = 40) 19.4 8.7 12.2 22.2 19.4 72.5
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Table 3 Biofilm-forming capacity of 248 methicillin-resistant strains of Staphylococcus aureus (MRSA) and percentages of their
adhesion genes related to antibiotics
Biofilm Adhesion gene Gentamycin % Ciprofloaxin % SXT % Erythromycin % Clindamycin % MDR % Total %
Strong (n = 52, 20.9%) FinbB 23.1 23.1 1.9 15.4 11.5 7.7 46.2
ClfA/ClfB 32.7 40.4 11.5 36.5 28.8 19.2 69.2
Ebps 42.3 46.2 21.2 44.2 34.6 32.7 71.2
Can 15.4 19.2 3.8 15.4 11.5 7.7 38.5
Eno 46.2 59.6 30.8 57.7 25.0 38.5 94.2
Icad 42.3 57.7 26.9 51.9 36.5 32.7 88.5
FinbA 34.6 44.2 13.5 38.5 26.9 21.2 71.2
Fib 26.9 34.6 5.8 28.8 21.2 17.3 46.2
Moderate (n = 115, 46.3%) FinbB 5.2 18.3 0.9 17.4 6.1 6.1 26.1
ClfA/ClfB 13.0 30.4 13.0 54.8 28.7 17.4 81.7
Ebps 12.2 31.3 13.9 53.0 27.0 18.3 79.1
Can 7.0 7.8 8.7 28.7 17.4 8.7 40.9
Eno 18.3 36.5 19.1 65.2 33.0 26.1 94.8
Icad 13.9 32.2 17.4 56.5 29.6 21.7 82.6
FinbA 9.6 28.7 9.6 50.4 24.3 12.2 78.3
Fib 7.8 26.1 7.0 43.5 22.6 10.4 64.3
Weak (n = 81, 32.6%) FinbB 3.7 14.8 7.4 24.7 8.6 6.2 88.9
ClfA/ClfB 13.6 34.6 66.7 51.9 33.3 17.3 82.7
CLFB 13.6 34.6 17.3 54.3 33.3 17.3 86.4
Ebps 11.1 30.9 14.8 46.9 30.9 14.8 75.3
Can 7.4 11.1 7.4 23.5 17.3 7.4 39.5
Eno 12.3 37.0 17.3 59.3 37.0 17.3 95.1
Icad 12.3 30.9 14.8 51.9 33.3 18.5 81.5
FinbA 13.6 30.9 14.8 51.9 33.3 17.3 82.7
Fib 9.9 29.6 8.6 45.7 28.4 11.1 69.1
Fig. 1 Biofilm phenotype and the source of strains of MRSA, i. e. tissues and lesions
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Discussion
Biofilm production by S. aureus has been identified as the
most important means of defense against host antagonis-
tic responses. Beside enabling bacterial colonization of
host tissues, it also prevents clearance of the bacteria by
antimicrobial agents and host immune responses [13],
leading to morbidity and mortality owing to the metastatic
spread of abscesses [14]. Here the ability among strains of
MRSA isolated from hospitalized- and out-patients to
form biofilm was studied, combining it with their clinical
molecular biological details and determining the presence
of genes encoding these virulence factors and its relation
to antibiotics. The SCCmec type IV was the most frequent
SCCmec type among the strains. Its presence in the spor-
adic strains among the 92.7% and the group of strains
from out-patients shows their great persistence [15].
SCCmec type IV is currently one of the most frequent
nosocomial SCCmec types and is found in several coun-
tries [16, 17].
The antimicrobial resistance patterns of strains of this
type varied considerably.
Here, 26.6% of the strains of MRSA with multi-
resistance to more than three antibiotics were of the
SCCmec type IV with 83.4% carried SCCmec type IVa
and all are biofilm producers. These results indicate that
the production of biofilm might be one of the crucial
factors increasing resistance to commonly used antibi-
otics. That deserve a special comment. This higher
MDR rely to protective nature of the biofilm, the bac-
teria growing in it are internally resistant to many antibi-
otics and the antibiotic resistance in the strains of the
bacteria residing in biofilm could increase up to 1000
times as seen by Neupane and colleagues [18]. The main
reasons for this may be difficulty in penetration of bio-
film by antibiotics, slow growth rate of the bacteria and
presence of antibiotic degradation mechanisms.
Moreover, the high resistance of the strains of MRSA
to erythromycin, ciprofloxacin,of which were moderate
biofilm producers with higher rate of studied adhesion
genes, particularly, eno gene. This agreed with the high
prevalence of drug resistance presented in a study done
in Iran where the resistance of strains of MRSA to cipro-
floxacin, erythromycin and gentamicin was 51.28, 87.18
and 71.8%, respectively [19]. It seems that misuse and
overuse of some antibiotics, including gentamicin, clin-
damycin, ciprofloxacin and erythromycin, have caused a
high prevalence of resistance to them in this region,
showing that empirical treatment of infections of strains
of MRSA at Palestinian hospitals with these antibiotics
may not be effective and they should not be used and
considered first-line drugs for the treatment of infections
of MRSA in the local population. Appropriate measures
are needed to prevent treatment failures. All the strains
were susceptible to vancomycin and more than two third
of the strains were susceptible to trimethoprim sulfa-
methoxazole. Vancomycin is reported to be the most ef-
fective antibiotic for Gram-positive bacteria, including
MRSA, but reduced susceptibility to both antibiotics has
been reported in some studies [20, 21]. Vancomycin and
other glycopeptides have remained the last options for
eradication of infections caused by S. aureus. The data
presented here also showed all the strains, producing
biofilm, were sensitive to vancomycin. This is consistent
with other researchers’ recommendation that vanco-
mycin, which is a very expensive drug, is the last anti-
biotic option and should be used sparingly.
The data presented here agree with susceptibility rates
in other countries [22]. Wang and colleagues [23] re-
ported a 78.6% susceptibility rate to trimethoprim-
sulfamethoxazole among strains of MRSA, which is of
concern and emphasizes the need for persistent moni-
toring of the development of antimicrobial resistance by
strains of S. aureus that leads to community- and
hospital-acquired infections. Here, we report a high rate
of SXT resistance (22.1%), which in the future could
increase as a consequence of horizontal transmissibility
of the dfrK gene, encoding for trimethoprim-resistance.
Here, phenotypic and genotypic evaluations, PCR and
crystal violet (CV) staining assays, were combined to
detect biofilm production in strains of S. aureus.. All the
strains were biofilm producers with variation in biofilm
mass. To understand the molecular mechanism of bio-
film production by strains of MRSA, in addition to the
icaD/icaA, sarA and agr group genes, the frequency of
nine selected genes involved in biofilm production were
detected. Many studies have shown the role and require-
ment of the intracellular adhesion locus (ica) in biofilm
production [24, 25]. The icaA and icaD genes determine
the ability of strains of S. aureus to produce biofilm by
mediating the synthesis of PIA which suggest that the
ica locus would be a good target in the therapy of im-
plant infections. There was a 100% agreement between
the genotypes and phenotypes of strains where all the
strains having icaD/icaA and producing biofilm, which
agreed with the findings of Liberto and colleagues [26]
and support those of Namvar and colleagues [27], who
reported that strains of S. aureus had no ability to pro-
duce biofilm, unless they were positive for the icaD gene.
Similar observations were reported by Grinholc and col-
leagues [28], who found that 91% of strains of MRSA
possessed the icaD gene. Contrarily, Arciola and col-
leagues [29], detected icaA and icaD genes in only 61%
of strains. The relatively low percentage of icaD positive
strains described by Arciola and colleagues [29] resulted
from the method of detection they used, in which
primers complementary to the sequence of the icaD
gene from Staphylococcus epidermidis, rather than
primers complementary to the sequences of the icaD
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and icaA genes from S. aureus were used. There was no
difference in the distribution of the ica genes in strongly
and weakly virulent strains, which agreed with the findings
of others [5, 30, 31]. The PIA mediates intercellular adher-
ence and accumulation of multilayer biofilms. In our study
the ica operon was present in all MRSA strains but strains
differed in biofilm mass. It is suggested that these strains
also used other systems to form biofilm such as protein A
(SpA) or fibronectin binding proteins.
Other contradictory published data stated that some
strains, in spite of the presence of the ica locus, do not
produce biofilm [25]. Recently, it has become evident
that the presence of PIA is not essential for the produc-
tion of biofilm in many strains of MRSA [32].
The ability to produce biofilm varied among the strains
of MRSA and also greatly among the other different geno-
types of S. aureus where an increasing number of different
adhesion molecules have been found. The frequency of
eno, clfA/clfB, fnbA, ebps, fib, cna, and fnbB genes was
found to be 94.8, 80.2, 78.2, 76.2, 62.2, 39.9 and 29.0%, re-
spectively (Table 2). While in other studies [33], showed
the frequency of eno, clfA/clfB, fnbA, ebps, fib, cna and
fnbB genes in strains of MRSA was 79, 97, 64, 12, 76, 56,
and 51%., respectively. Yang and colleagues [34], showed
the prevalence of genes associated with biofilm in the
ST59-SCCmec IV-t437 clone were icaA (100.0%), icaD
(97.3%), fnbpA (100.0%), fnbpB (0), clfA (100%), clfB
(100%), cna (2.7%), bbp (0), ebpS (88.5%). This explains
the discrepancies between studies, which is related to dif-
ferences in the frequency of clones among different coun-
tries. The gene bap, whose protein was, probably, the first
protein shown to have a role in biofilm production in S.
aureus, was not tracked in our study. It is said to be absent
in all strains, which agrees with the study by Serray and
colleagues [35]. However, the absence of bap indicates
that the ica-dependent mechanism, might be primarily re-
sponsible for adhesion and biofilm production in strains
as suggested by Vautor and colleagues [36].
The fnbA and fnbB genes appear to be essential to the in-
vasion and adhesion of bacteria and might be correlated
with their biofilm-producing ability. In this study, a low
percentage (29.0%) of occurrence of the fnbB gene was
observed.
However, Arciola and colleagues [29], found a high
occurrence of this gene (99.5%). This could partly be
ascribed to the different region of the locus analyzed by
the couple of primers. However, the fnbA gene was de-
tected in 76.2% of the strains, which is similar to what
was observed by Ikawaty and colleagues [28]. There is a
significant difference between strains from blood and those
from wounds regarding the presence of the fnbB gene.
About a third of the strains (35.9%) from wounds carried
the gene. However, only 14.7% of the strains from blood
carried the fnbB gene. A comparative analysis between
strains of MRSA and strains of MSSA showed that the
fnbpA gene was more likely to be present in strains of
MRSA whereas the fnbB gene was more likely to be
present in strains of MSSA [34]. However, other studies
did not find a correlation between methicillin resistance
and the prevalence of genes associated with biofilm [37].
This disagreement may be owing to the specific clonal
complexes of strains that might contain an exclusive com-
bination of surface-associated and regulatory genes [38].
This study indicated that the clfA and the clfB genes
were present in 82.7% of the strains and constituted the
bound coagulase of S. aureus. This study showed that
the strains from all sources except urine (43.5%) had a
high percentage of, both, the clfA and the clfB genes.
Elastin is the main component of elastic fibers, which
are proteins that provide strength and flexibility to
connective tissue and is highly expressed in the lung, skin
and blood vessels and widely expressed at low levels in
most mammalian tissues [39]. Elastin binding protein of S.
aureus (EbpS), said to facilitate binding of bacteria to elas-
tin rich host, extracellular cell matrix (ECM) [40]. EbpS is
a cell-surface molecule the mediates binding of a bacterial
cell to soluble elastin peptides and tropoelastin [39]. The
presence of the ebpS gene was found in 76.2% of the
strains studied here. Another gene, shown to have a cru-
cial role in binding to extracellular matrix, fibrinogen (fib),
was also detected in 62.2% of the strains. This agreed with
the findings of Pereyra and colleagues [41] who reported
higher percentages of 90 and 71.7%, respectively. This
contradicted the findings of [35], where the fib and ebpS
genes were detected at a rates of 5.66 and 9.34% of strains.
The difference in the prevalence of these genes is probably
owing to the distribution of variants of the genotype of S.
aureus in different countries. The incidence of cna was
39.9% in the strains of MRSA studied here. This agreed
with the findings of Nashev and colleagues in Italy [36],
and in Bulgaria [29], who reported of similar rates of
46.7% and occurrence of this gene (11.32%) was reported
by serray and colleagues [35].
The expression of several virulence factors of S. aureus
was shown to be controlled by certain genetic loci, par-
ticularly, the staphylococcal accessory regulator, which
consists of the sarA gene and accessory gene regulator
(agr) locus (Jarraud et al., 2002). In studies done by
other colleagues [42–44] all their strains of MRSA har-
boring the icaADBC genes were positive for the sarA
gene, which was contradicted by this study.
The ica genes are regulated by multiple genes such as
the sarA, and agr genes. They might interact with each
other and regulate biofilm production. The sarA gene has
an effect on many virulence genes of S. aureus and
appears to be a master controller of biofilm production,
promoting synthesis of fibronectin and fibrinogen binding
proteins and also toxins for tissue spread while repressing
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expression of protein A and the four major extracellular
proteases governed by the SspA, SspB, Aur, and ScpA genes
[2, 45]. Here, about two third of the strains genotypically
possessed the sarA gene and phenotypically produced
biofilm and the fnbB gene was common among strains that
were strong producers of biofilm (34.6%) suggesting the
importance of PIA-independent biofilm production in these
strains. Interestingly in this study, a higher rate of the
strains of MRSA possessed the fnbA, fnbB and the fib gene
which were also positive for the sarA gene.
Different levels of sarA expression in clinical isolates
of S. aureus have been related to differences in extracel-
lular protease production [46] and that sarA can directly
and positively regulate levels of fnbA transcription [47].
On the other hand, Pozzi and colleagues [48] reported
that biofilm production in strains of MSSA mainly occurs
via PIA synthesis while in strains of MRSA it is related
more to adhesion owing to the fnbB gene. So further
investigation and studies are needed.
Strains producing biofilm have a very high tendency to
exhibit antimicrobial multidrug resistance. However,
46.9% of the strains with the sarA gene were MDR, and
more than halfwere shown to be resistant to erythro-
mycin, ciprofloxacin, clindamycin and gentamycin This
makes sarA an attractive target for antimicrobial drug
development [49, 50]. Surprisingly, most of the isolates
from wounds and pus were sarA positive.
To date, strains of S. aureus have been classified into
four main groups, agr -I to agr-IV, according to differences
in their agr genes, (Jarraud et al., 2002). The central role
of the agr-encoded quorum-sensing system in the regula-
tion of virulence makes it an attractive target for anti-
microbial drug development. However, mutations in the
agr gene or interference with agr gene activity by a cross-
inhibiting agr pheromone can promote the production of
colonization factors like MSCRAMMs and biofilm devel-
opment [6]. All four agr groups were found among the
strains studied here, with agr group I in large proportion
and more than half of the samples from wounds belonged
to this group.
Previous studies also found the agr group I to be the pre-
dominant type [51]. Here, 14.5%strains could not be typed
by the same method, possibly, owing to a deletion in the agr
locus. It is noteworthy that the strains in agr group III had a
greater number of the fnbA, ebps, cna, eno and fib genes,
and most of the toxin producing strains also belonged to
agr group III while the strains in agr group-I had a greater
number of fnbB, clfA and clfB. Regarding the relationship
between agr group-III and biofilm production, the data re-
vealed that strains belonging to agr group-III had a greater
number of weak and moderate producers of biofilm com-
pared to those belonging to agr group-I, which, interestingly,
had more and stronger biofilm-producing strains. Also, the
strains belonging to agr group-III had higher antibiotic
resistance to erythromycin and clindamycin compared to
those belonging to agr group-I, which carried a greater
number of strains resistant to ciprofloxacin (58.2%), genta-
mycin (27.6%) and SXT (19.4%). The presence of the com-
bination of genes studied here, where 3.9% of the strains
possessed all the genes examined and including the icaA
and icaD genes, could mean that they might have a selective
advantage, e. g. a good genetic capacity for adherence and
better colonization of hosts. Moreover, the coexistence of
icaA, icaD, agr and sarA and eight MSCRAMM genes in
11.7%of the strains agree with the findings of Tristan and
colleagues [52]. The most common biofilm gene combin-
ation among the strains of MRSA was that of agr, sarA, eno,
clfA/clfB, fnbA, ebps and fib genes. The mechanism of multi-
drug resistance is said to result from close cell to cell contact
in the biofilm that makes the transfer of plasmids containing
MDR genes among them easier, which limits the therapeutic
options, creating an economic and social burden to the
healthcare system. Biofilm development is a very compli-
cated process that involves numerous factors. The present
survey study is a first step. It provides preliminary results for
further detailed future studies. One limitation of the study,
is the inability to use control S. aureus strains that lack each
of the gene tested in this study. Mutants defective in either;
IcaA, IcaD, agr, saR, each of the genes that code for the
MSCRAAM proteins. This way, biofilm development by the
mutant would be measured directly to that produced by the
tested isolates.
Conclusion
The present study revealed that MRSA strains isolated
from clinical materials from hospitalized patients pro-
duced biofilm and possessed icaA and icaD genes, with
differed biofilm mass, indicating that these strains may
also use other system to form biofilm. The high rate of
biofilm production among the strains of S. aureus and
high rate of drug resistance among the biofilm producing
strains, detection of biofilm adhesion genes indicating
staphylococcal virulence markers and showing that the
burden of MRSA in the Palestinian West Bank region was
high. Further, clinical strains of S. aureus and the ability of
several strains of MRSA to produce biofilm in the absence
of sarA and agr genes needs further investigation to clarify
the mechanism underlying the production of biofilm inde-
pendent of the activity of the sarA and agr genes. On the
basis of the antimicrobial susceptibility testing, aworri-
some increase in erythrocyte and ciprofloxacin resistance
was observed, which deserves future attention.
Methods
Clinical strains
A Total of 248 strains of MRSA were isolated from
patients admitted to four Palestinian hospitals located in,
Jerusalem, Ramallah, Bethlehem and Nablus. The study
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period was between November 2015 and April 2018.
Most came from the Al-Makassed Islamic Charitable So-
ciety Hospital in Jerusalem. MRSA ATCC 4300 and S. epi-
dermidis ATCC 12228 were reference strains provided by
Dr. Adham abu Taha of the Palestinian Al Najah Univer-
sity. All the strains were stored at − 80 °C in brain-heart
infusion (BHI) (Himedia, Mumbai, India) plus 25% gly-
cerol (EMPROVE, Darmstadt, Germany). This study was
approved by the Research Ethical Committee of Al-Quds
University. Written and informed consents were sent for
the participating hospitals and clinics.
Identification of isolates
All isolates were identified by classic microbiological
methods: colony morphology; mannitol fermentation;
Gram staining, catalase test; coagulase test. Antibiotic sus-
ceptibility was determined by the disc-diffusion method
(Oxoid, Basingstoke, UK).
The antibiotics used in this study were cefoxitin (30 μg),
penicillin (10U), amoxicillin/clavulanic acid (10 μg), ceftri-
axone (30 μg), meropenem (10 μg), erythromycin
(15 μg), ciprofloxacin (5 μg), clindamycin (10 μg), genta-
micin (10 μg), SXT (25 μg) and vancomycin (30 μg).
Apart from β-lactam, multi drug resistance (MDR) for
MRSA was defined as resistance to at least three of the
antimicrobial agents.
Isolates were classified as susceptible or resistant to
methicillin according to the criteria of the Performance
Standards for Antimicrobial Susceptibility Testing (2002).
Methicillin resistant strains of S. aureus were detected by
the disk-diffusion method, using a cefoxitin (FOX) disk
(30 μg) on Mueller-Hinton agar plates according to the
Clinical Laboratory Standards Institute (CLSI) guidelines
[53]. An infection was considered healthcare-associated if
the date of the infection occurred on or after the third day
of admission to an inpatient facility.
Genomic DNA extraction
Genomic DNA was extracted from overnight fresh cultures
on Trypticase Soy Broth (TSB), using either a ‘Nucleospin’
DNA extraction kit (Macherey-Nagel, Germany) [54] or a
Presto Mini gDNA Bacteria Kit (Geneaid).
Molecular typing
Detection of the mecA gene and SCCmec typing by PCR
The mecA gene and femA endogenous control gene were
amplified in the same reaction. The primers used to amplify
the mecA gene were mecA1F (5′-GTAGAAATGACTGAA
CGTCCGATAA-3′) and mecA2R (5′-CCAATTCCACAT
TGTTTCGGTCTAA-3′) [16]. The primers used to amplify
the femA gene were femA GFEMAR-1(5′-AAAAAAGCA-
CATAACAAGCG-‘3) and femA GFEMAR-2 (5’-GATAAA
GAAGAAACCAGCAG-‘3) [55]. Each reaction used 1 μM
of each primer and 2 μl of DNA, and was performed in
Thermo Scientific Reddy Mix PCR mater Mix conc 2X in a
final volume of 25 μl. The thermal cycling program for
detecting both genes was: one cycle of initial denaturation
at 95 °C for 15min; 34 cycles of denaturation at 95 °C for
30 s; annealing at 58 °C for 30 s; extension at 72 °C for 1
min; a final extension at 72 °C for 5min.
The amplified products (femA: 132 bp and mecA: 310
bp) were resolved in a 2.5% agarose gel. The fragments
were stained with ethidium bromide and visualized and
photographed using a gel documentation system. A 100
bp ladder was run as a molecular weight marker. Isolates
that were confirmed to be methicillin sensitive by the
disk diffusion method and then by the absence of the
mecA gene were excluded from this study.
Exposing the existence of SCCmec types and subtypes
I, II, III, IVa, IVb, IVc, IVd, and V of all the isolates of
MRSA was done by the multiplex PCR assay described
by Boye and colleagues [56], which used 9 pairs of
primers that are unique and specific for the above men-
tioned SCCmec types and subtypes. Exposing the exist-
ence of SCCmec subtype IV was done by the multiple
PCR assay described by Zhang et al. [57]. Isolates unable
to be typed were designated NT. Amplification was per-
formed as described by Hadyeh and colleagues (2019).
Detection of biofilm genes
Simplex and multiplex PCRs were used to detect the
following genes in all the isolates of MRSA: bap (encod-
ing biofilm-associated protein); ebpS (encoding elastin-
binding protein); eno (encoding laminin-binding pro-
tein); fib (encoding fibrinogen-binding protein); fnbA
(encoding fibronectin-binding protein A); fnbB (encod-
ing fibronectin-binding protein B); clfA and clfB (encod-
ing clumping factors A and B); cna (encoding collagen-
binding protein). The specific primers and PCR thermal
profiles used for these genes were as described by others
[3, 35, 52]. The amplified products cna: 423 bp; ebpS:
652 bp; eno: 302 bp; fnbA: 127 bp; fnbB: 524 bp; fib: 404
bp; bap: 971 bp; clfA: 292 bp and clfB: 205 bp were
resolved in a 2.5% agarose gels.
Detection of icaD and icaA genes
The presence of icaD DNA was detected as described by
Gowrishankar and colleagues [58]. The specific forward
primer was icaD (5’ATG GTC AAG CCC AGA CAG
AG3′) and the specific reverse primer was icaD (5’CGT
GTT TTC AAC ATT TAATGC AA3’). For icaD-negative
strains, detection of the icaA gene was done using the for-
ward primer icaAF (5’ACA CTT GCT GGC GCA GTC
AA 3’) and reverse primer icaAR (5’TCTGGAACCAA-
CATCCAACA3’) as proposed by [30]. The icaD and icaA
genes were amplified by a PCR to generate 188 bp and
198 bp fragments, respectively.
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Determination of agr group and sarA gene
The agr typing was done by a multiplex-PCR to determine
the agr allele types I to IV, using the agr group specific
primers and amplification conditions as described by [30].
The agr system groups were classified based on the hyper-
variable domain of the agr locus and their responding
receptors separated into four major agr groups. Pan-agr,
corresponding to the conserved sequences of agrB, was
used in all the reactions.
Based on the agr locus polymorphism, four reverse
primers were used, each specific for the amplification of
a single agr group. The agr groups were identified by
amplicon size: 440 bp for agr I; 572 bp for agr II; 406 bp
for agr III; 588 bp for agr IV.
SarA DNA was detected, using the forward primer sarAF
(5’CCCAGAAATACA ATCACTGTG’3) and reverse pri-
mer sarAR (5′ AGTGCCATTAGTGCAAAACC’3) as de-
scribed by Gowrishankar and colleagues [58], which
produced an amplicon of 720 bp.
Biofilm formation assay
The isolates of MRSA were tested for biofilm formation.
The assay was performed in polystyrene 96-well microtiter
plates that had flat-bottomed wells that were stained with
crystal violet according to Stepanovic and colleagues [59].
Staphylococcus epidermidis ATCC 12228, and MRSA
ATCC 43300 were used as biofilm-producing controls.
Trypticase soy broth medium was used as a negative con-
trol to determine background OD. The microtiter plate
method was done as described by Atshan and colleagues
[60]. The amount of biofilm formed was estimated by
reading the optical density (OD) at 570 (630) nm and
recording the absorbance using a microplate reader (RT-
2100C, Rayto, IVD). The average OD value of each tripli-
cate of experimental samples and negative controls was
calculated. Biofilm formation was separated into four
categories according to [19]: 1, ODs ≤ODc = no biofilm
produced, therefore a non-producer; 2, ODc ≤ODs ≤ 2×
ODc = weak biofilm produced, therefore a weak producer;
3, 2× ODc ≤ODs ≤ 4 ×ODc =moderate biofilm produced,
therefore a moderate producer; 4, 4× ODc <ODs = strong
biofilm produced, therefore a strong producer, where
ODc =OD of the negative control and ODs =OD of the
experimental samples.
Statistical analysis
Data analysis was done using SPSS software version 20.0
(IBM, Armonk, USA). Pearson’s chi-square was used in the
statistical analysis. A P value less than 0.05 was considered
statistically significant.
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